Physician profile
Hani Al-Halabi
NPI 1619315264
$945.89
in general payments reported to CMS, 2019-2025
17 companies · $74.13 in 2025
The $74.13 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $168 · 2025: $74.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $213.34 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $166.19 | 2019-2020 | |
| Amgen INC. | $162.96 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $75.48 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.95 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $48.66 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $27.31 | 2019 | |
| Progenics Pharmaceuticals, INC. | $27.09 | 2025 | |
| Eisai INC. | $27.07 | 2019 | |
| Blue Earth Diagnostics | $24.65 | 2025 | Posluma |
| Teleflex LLC | $22.39 | 2025 | Barrigel |
| Ferring Pharmaceuticals INC. | $21.35 | 2020 | |
| Janssen Biotech, INC. | $18.80 | 2019 | |
| Novocure INC. | $14.37 | 2019 | |
| Daiichi Sankyo INC. | $13.02 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.98 | 2020 | |
| Exelixis INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Al-Halabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.